Oral Insulin, sub lingual - A product under development at MKPPL
Oral Insulin, sub lingual – A product under development at MKPPL.
Oral insulin, which refers to insulin that is taken by mouth rather than being injected, has been a subject of research and development for many years. We at MKPPL are working on a sub lingual formulation. While there have been challenges in developing an effective oral insulin formulation, if successfully developed, oral insulin could offer several benefits. Here are some potential advantages:
Convenience: One of the most significant advantages of oral insulin is its convenience compared to traditional injectable insulin. Many individuals with diabetes require multiple daily insulin injections, which can be cumbersome and uncomfortable. Oral insulin would eliminate the need for injections, making it more convenient and less invasive for patients.
Improved compliance: The ease of taking oral insulin could lead to better compliance with treatment regimens. Some individuals with diabetes may be reluctant to take insulin injections due to fear of needles or the social stigma associated with injections. Oral insulin may help overcome these barriers, leading to improved adherence to therapy and better diabetes management.
Reduced pain and discomfort: For individuals who have a fear of needles or experience pain and discomfort during injections, oral insulin could provide a more comfortable alternative. This could be particularly beneficial for children, older adults, and individuals with needle phobia.
Better glycemic control: Oral insulin has the potential to provide more precise and rapid control of blood glucose levels compared to other oral medications used to manage diabetes. Insulin, when taken orally, can more closely mimic the natural insulin response of the body, leading to improved glycemic control and reduced risk of complications associated with high or low blood sugar levels.
Lower risk of infection: Injectable insulin requires the use of needles, which increases the risk of infection at the injection site. By eliminating the need for injections, oral insulin could reduce the risk of local infections, abscesses, or other complications associated with injection sites.
Our product so far is stable and is based on human insulin and is long lasting .
It’s important to note that while oral insulin holds promise, there are still challenges to overcome in terms of formulation, we at MKPPL are working to overcome some of them like absorption, and ensuring its effectiveness. Extensive research and clinical trials are ongoing to develop a reliable and effective oral insulin product.
We are looking for serious partners to take this ahead.